# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug. iTeos and GSK en...
iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery a...
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ITeos Therapeutics (NASDAQ:ITOS) with a Buy and raises the ...
ITOS: 39% | iTeos Therapeutics shares are trading higher after the company announced a $120 million registered direct offering ...